# A Study of SHR-4375 in Subjects With Solid Tumors

Source: https://onco.cc/trials/nct06764628/  
OnCo record `nct06764628` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SHR-4375 in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

A Study of SHR-4375 in Subjects With Solid Tumors is a phase 1/2 interventional study registered as NCT06764628 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 208 participants planned, started 2025-01-09 and due to reach its primary completion in 2027-05. Interventions recorded: SHR-4375.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06764628
- Phase: 1/2
- Setting: An Open-label, Single-arm, Multicenter Phase I/II Clinical Study of SHR-4375 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 208

## Sources

- ClinicalTrials.gov NCT06764628: https://clinicaltrials.gov/study/NCT06764628

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06764628.json